Video

Urology Times 50 Innovations Series: LHRH analogues in prostate cancer

Author(s):

Urology Times staff

“LHRH therapies are not going away. They are the standard of care,” says E. David Crawford, MD.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      As part of the Urology Times' 50th Anniversary Innovation Celebration, E. David Crawford, MD, discusses the development of luteinizing hormone-releasing hormone (LHRH) agonists and antagonists in prostate cancer. Crawford is a professor of urology at the University of California, San Diego.

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      2 experts in this video
      Transitioning to Oral ADT and Drug-Drug Interactions
      Timothy McClure, MD, highlights data on IRE for prostate tissue ablation
      Timothy McClure, MD, highlights data on IRE for prostate tissue ablation
      Advances across urology: Insights from UNC faculty
      Advances across urology: Insights from UNC faculty
      Related Content
      Novel alpha particle therapy holds promise in prostate, bladder cancer
      August 21st 2025

      Novel alpha particle therapy holds promise in prostate, bladder cancer

      Robert B. Den, MD
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      August 21st 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      August 21st 2025

      PSMA PET/CT prior to salvage radiotherapy may improve overall survival

      Hannah Clarke
      Dr. Murphy on increasing diversity in cancer clinical trials
      August 21st 2025

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      FDA grants de novo authorization to ArteraAI Prostate
      August 21st 2025

      FDA grants de novo authorization to ArteraAI Prostate

      Hannah Clarke Benjamin P. Saylor
      Study offers insights into optimal patient selection for HIFU in prostate cancer
      August 21st 2025

      Study offers insights into optimal patient selection for HIFU in prostate cancer

      Hannah Clarke
      © 2025 MJH Life Sciences

      All rights reserved.